Cubist Systematic Strategies, LLC Recursion Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $162,660 - $276,504	17,816 Added 135.96%	30,920 $308,000
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $66,699 - $141,392	13,104 New	13,104 $129,000
Q1 2023 May 15, 2023	BUY	$6.42 - $9.64 $1.58 Million - $2.38 Million	246,829 Added 154.43%	406,662 $2.71 Million
Q4 2022 Feb 14, 2023	BUY	$7.16 - $12.7 $345,527 - $612,876	48,258 Added 43.25%	159,833 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$7.83 - $13.6 $690,347 - $1.2 Million	88,167 Added 376.65%	111,575 $1.19 Million
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.26 $329,313 - $605,048	-65,340 Reduced 73.62%	23,408 $191,000
Q1 2022 May 16, 2022	BUY	$6.16 - $18.03 $338,621 - $991,127	54,971 Added 162.75%	88,748 $635,000
Q4 2021 Feb 14, 2022	BUY	$16.14 - $21.86 $98,308 - $133,149	6,091 Added 22.0%	33,777 $579,000
Q3 2021 Nov 15, 2021	BUY	$19.03 - $41.33 $268,056 - $582,174	14,086 Added 103.57%	27,686 $637,000
Q2 2021 Aug 16, 2021	BUY	$18.0 - $37.42 $244,800 - $508,912	13,600 New	13,600 $496,000

286

242M

1.35M

2.32M

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.12B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.